Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function Irinotecan is active against a variety of malignancies; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback